Cellular Immunotherapies for Multiple Myeloma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (31 August 2021) | Viewed by 16597
Special Issue Editor
Interests: tumor immunology; cancer immunotherapy; CAR T cells; cancer vaccines; T cells; monoclonal antibodies; multiple myeloma; stem cell transplantation; adoptive immunotherapy
Special Issue Information
Dear Colleagues,
The introduction of cellular immunotherapies using genetically modified T cells has revolutionized the treatment of patients with B cell lymphomas. However, despite the progress made in this field, similarly effective immunotherapeutic approaches have not yet been identified for patients with many other hematologic malignancies.
In this Special Issue, we will outline the most promising novel cellular immune strategies for patients with multiple myeloma. This will include but is not limited to donor lymphocyte infusions (DLI), bone marrow-infiltrating lymphocytes, chimeric antigen receptor (CAR) T cells, and T cell receptor (TCR)-transduced T cells. In addition, we will highlight combinatorial approaches, e.g., with immune checkpoint inhibitors or oncolytic viruses, which will hopefully further optimize cellular immunotherapies for myeloma and lead to deep and durable responses and, hopefully, even cures.
Dr. Djordje Atanackovic
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Cellular immunotherapies
- Cancer immunotherapy
- Multiple Myeloma
- CAR T cells
- T cell receptor